secwatch.observer — SEC 8-K summary
======================================

Issuer:     SIGA TECHNOLOGIES INC (SIGA)
CIK:        0001010086
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001140361-24-048907
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped
--------------------------------------------------------------------------------

- Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
- Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.
- Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.
- CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.
- Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/0001140361-24-048907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/ef20039836_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-048907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer